Lestaurtinib

Overview

Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC 50 s of 2, 25 and 0.9 nM for FLT3 , TrkA and JAK2 , respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor.

Application

Products | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Trk Receptor | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > STAT | Products > Signaling Pathways > JAK | Products > Signaling Pathways > FLT3

Product Information

• Catalog No.: HY-50867
• CAS No.: 111358-88-4
• Molecular Formula: C26H21N3O4
• Molecular Weight: 439.46
• Purity: 99.66%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: 2.5 mg/mL (5.69 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source